1. AIMS Trial Study Group (1988) ,Effect of intravenous APSAC on mortality after acute myocardial infarction; preliminary report of a placebo-controlled clinical trial. The Lancet I, 545–549.
2. Albrightson CR, Baenziger NL, Needleman P (1985),Exaggerated human vascular cell prostaglandin biosynthesis mediated by monocytes: role of monokines and interleukin 1. J Immunol 135: 1872–1876.
3. Annand JC (1986), Denatured bovine immunoglobulin pathogenic in atherosclerosis. Atherosclerosis 59: 347–35.
4. Assmann G (1991), Is there an increased risk of non-cardiac death after lipid lowering treatment ? Controversies in Cardiology 3, 5–8, 1991.
5. Assmann G, Schulte H (1988) ,The prospective cardiovascular Münster(PROCAM) ,study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. ,Am Heart J 116, 1713–1724.